MKGAY - Merck KGaA raises stake in Precigen through convertible notes Shares up 9%
Merck KGaA (MKGAY) wholly owned subsidiary, Ares Trading S.A. converts $25M convertible notes in Precigen (PGEN) ahead of the December 2020 maturity date, thereby raising its stake from 11,6% to 14.8%. Precigen and Merck KGaA started back in 2015, whereby both the companies signed an agreement to develop and commercialize CAR-T cancer therapies utilizing Precigen's proprietary sleeping beauty non-viral gene integration technology.Shares are up 9% premarket.
For further details see:
Merck KGaA raises stake in Precigen through convertible notes, Shares up 9%